Adipose-derived stem cell-derived extracellular vesicles inhibit neuroblastoma growth by regulating GABBR1 activity through LINC00622-mediated transcription factor AR

Guo, Mengguo; Li, Dongpeng; Feng, Yawen; Yang, Bo

doi:10.1002/jlb.1mia0321-164r

Cited by 10 publications

(5 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent research showed that ADAMTS9-AS2 could restrict the deterioration of esophageal cancer and it also has the ability to function as a prognostic lncRNA in LUAD [ 39 ]. As to LINC00622, it is tightly associated with transcriptional factor androgen receptor and essential neuroblastoma progression [ 40 ]. Notably, MIR99AHG not only can influence the epithelial-mesenchymal transition in LUAD but also encourage the differentiation of bone marrow mesenchymal stem cells [ 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

Molecular subgroup establishment and signature creation of lncRNAs associated with acetylation in lung adenocarcinoma

Chen,

Wang,

Shao

et al. 2024

Aging

View full text Add to dashboard Cite

Background: The significance of long non-coding RNAs (lncRNAs) as pivotal mediators of histone acetylation and their influential role in predicting the prognosis of lung adenocarcinoma (LUAD) has been increasingly recognized. However, there remains uncertainty regarding the potential utility of acetylation-related lncRNAs (ARLs) in prognosticating the overall survival (OS) of LUAD specimens. Methods: The RNA-Seq and clinical information were downloaded from The Cancer Genome Atlas (TCGA). Through the differential analysis, weighted correlation network analysis (WGCNA), Pearson correlation test and univariate Cox regression, we found out the prognosis associated ARLs and divided LUAD specimens into two molecular subclasses. The ARLs were employed to construct a unique signature through the implementation of the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm. Subsequently, the predictive performance was evaluated using ROC analysis and Kaplan-Meier survival curve analysis. Finally, ARL expression in LUAD was confirmed by quantitative real-time PCR (qRT-PCR). Results: We triumphantly built a ARLs prognostic model with excellent predictive accuracy for LUAD. Univariate and multivariate Cox analysis illustrated that risk model served as an independent predictor for influencing the overall survival OS of LUAD. Furthermore, a nomogram exhibited strong prognostic validity. Additionally, variations were observed among subgroups in the field of immunity, biological functions, drug sensitivity and gene mutations within the field. Conclusions: Nine ARLs were identified as promising indicators of personalized prognosis and drug selection for people suffering with LUAD.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular subgroup establishment and signature creation of lncRNAs associated with acetylation in lung adenocarcinoma

Chen,

Wang,

Shao

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…Recent research showed that ADAMTS9-AS2 could restrict the deterioration of esophageal cancer and it also has the ability to function as a prognostic lncRNA in LUAD [39]. As to LINC00622, it is tightly associated with transcriptional factor androgen receptor and essential neuroblastoma progression [40]. Notably, MIR99AHG not only can in uence the epithelial-mesenchymal transition in LUAD but also encourage the differentiation of bone marrow mesenchymal stem cells [41,42].…”

Section: Discussionmentioning

confidence: 99%

Molecular Subgroup Establishment and Signature Creation of lncRNAs Associated with Acetylation in Lung Adenocarcinoma

Wang

Shao

Guo

et al. 2023

Preprint

View full text Add to dashboard Cite

Background The long non-coding RNAs (lncRNAs) have progressively been acknowledged as crucial intercessors of histone acetylation and play an authoritative role in lung adenocarcinoma (LUAD) prognosis. Despite this, it is still unclear whether acetylation-related lncRNAs (ARLs) could be utilized to forecast the overall survival (OS) of LUAD specimens. Methods The RNA-Seq and clinical information of 501 LUAD specimens and 56 corresponding paracancerous tissue specimens were downloaded from The Cancer Genome Atlas (TCGA). Through the differential analysis, Weighted correlation network analysis (WGCNA), Pearson correlation test and univariate Cox regression, we found out the prognosis associated ARLs and divided LUAD specimens into two molecular subclasses. Utilizing those ARLs, a novel signature was built by adopting Least absolute shrinkage and selection operator (LASSO) algorithm. ROC analysis and Kaplan–Meier survival curve were subsequently exercised to examine the predictive performance. Then based on the ARLs model, we exploited bioinformatics techniques to analyze the signaling pathways and biological roles, immunity, drug efficacy, and tumor somatic mutation. Next, univariate and multivariate Cox analysis were utilized to determine if the signature was an isolated predictor. Finally, ARL expression in LUAD was confirmed by quantitative real-time PCR (qRT-PCR). Results We triumphantly built a ARLs prognostic model with excellent predictive capability for LUAD, including ADAMTS9-AS2, AF131215.6, CYP4F26P, LINC00622, LINC00639, LINC00968, MIR22HG, MIR99AHG and WWC2-AS2. Univariate and multivariate Cox analysis illustrated that risk model was an isolated predictor for affecting the OS of LUAD. A nomogram showed robust prognostic validity. There were also diversities between subgroups in the field of immunity, biological functions, drug sensitivity and gene mutations. Conclusions Nine ARLs were identified as promising indicators of personalized prognosis and drug selection for people suffering with LUAD.

show abstract

“…MiR-431-5p carried by umbilical cord MSC-derived sEVs demonstrated inhibitory effects on PRDX1 , including restricted CRC cell line growth [ 67 ]. LINC00622 included in adipose-derived stem cell-derived sEVs promoted gamma-aminobutyric acid B-type receptor 1 and inhibited neuroblastoma cell growth [ 68 ]. Plant-derived sEVs also demonstrated anti-tumor effects.…”

Section: Sevs As An Active Pharmaceutical Ingredient For Cancer Therapymentioning

confidence: 99%

Emerging Roles of Using Small Extracellular Vesicles as an Anti-Cancer Drug

Joo,

Suh,

et al. 2023

IJMS

View full text Add to dashboard Cite

Small extracellular vesicles (sEVs) are emerging as a novel therapeutic strategy for cancer therapy. Tumor-cell-derived sEVs contain biomolecules that can be utilized for cancer diagnosis. sEVs can directly exert tumor-killing effects or modulate the tumor microenvironment, leading to anti-cancer effects. In this review, the application of sEVs as a diagnostic tool, drug delivery system, and active pharmaceutical ingredient for cancer therapy will be highlighted. The therapeutic efficacies of sEVs will be compared to conventional immune checkpoint inhibitors. Additionally, this review will provide strategies for sEV engineering to enhance the therapeutic efficacies of sEVs. As a bench-to-bedside application, we will discuss approaches to encourage good-manufacturing-practice-compliant industrial-scale manufacturing and purification of sEVs.

show abstract

Adipose-derived stem cell-derived extracellular vesicles inhibit neuroblastoma growth by regulating GABBR1 activity through LINC00622-mediated transcription factor AR

Cited by 10 publications

References 49 publications

Molecular subgroup establishment and signature creation of lncRNAs associated with acetylation in lung adenocarcinoma

Molecular subgroup establishment and signature creation of lncRNAs associated with acetylation in lung adenocarcinoma

Molecular Subgroup Establishment and Signature Creation of lncRNAs Associated with Acetylation in Lung Adenocarcinoma

Emerging Roles of Using Small Extracellular Vesicles as an Anti-Cancer Drug

Contact Info

Product

Resources

About